But some compounding pharmacies are now trying to continue this practice after a drug shortage endsskirting FDA safety regulations and oversight, and potentially jeopardizing patient health. Compounding pharmacies lower regulatory compliance costs can contribute to a lower price point, which is frequently emphasized in direct-to-consumer advertising such as a recent Super Bowl ad for compounded GLP-1s watched by 123 million people
This is particularly important for women using GLP-1 medications, as these factors can also influence the medication's effectiveness
Heres a brief overview: Wegovy ( semaglutide ), Zepbound ( tirzepatide ), and Foundayo ( orforglipron ) are approved for weight management in people with : Obesity aka, a body mass index (BMI) of 30 or higher Overweight (BMI of 27 or higher) along with a weight-related condition, such as high blood pressure or high cholesterol Wegovy is also approved for adults with certain forms of fatty liver disease and lowering the risks of cardiovascular events such as heart attack and stroke in certain at-risk populations with overweight or obesity
Starting Dose 0.15-0.30 mg/day (approx
If you don't know the exact concentration in your vial, you're guessing at your dose